The estimated Net Worth of Tim Demuth is at least 500 千$ dollars as of 13 May 2022. Dr Demuth owns over 6,000 units of Pieris Pharmaceuticals Inc stock worth over 104,940$ and over the last 3 years he sold PIRS stock worth over 0$. In addition, he makes 395,162$ as Sr. VP & Chief Medical Officer at Pieris Pharmaceuticals Inc.
Dr has made over 1 trades of the Pieris Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of PIRS stock worth 10,260$ on 13 May 2022.
The largest trade he's ever made was buying 6,000 units of Pieris Pharmaceuticals Inc stock on 13 May 2022 worth over 10,260$. On average, Dr trades about 2,000 units every 0 days since 2021. As of 13 May 2022 he still owns at least 6,000 units of Pieris Pharmaceuticals Inc stock.
You can see the complete history of Dr Demuth stock trades at the bottom of the page.
Dr. Tim Demuth M.D., Ph.D. is the Sr. VP & Chief Medical Officer at Pieris Pharmaceuticals Inc.
As the Sr. VP & Chief Medical Officer of Pieris Pharmaceuticals Inc, the total compensation of Dr D at Pieris Pharmaceuticals Inc is 395,162$. There are 5 executives at Pieris Pharmaceuticals Inc getting paid more, with Stephen Yoder having the highest compensation of 1,593,600$.
Dr D is 47, he's been the Sr. VP & Chief Medical Officer of Pieris Pharmaceuticals Inc since . There are 8 older and 8 younger executives at Pieris Pharmaceuticals Inc. The oldest executive at Pieris Pharmaceuticals Inc is Peter Kiener, 68, who is the Independent Director.
Tim's mailing address filed with the SEC is 255 STATE ST., 9TH FLOOR, BOSTON, MA, 02109.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over 24,745,707$ worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth 3,376,410$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Advisors Llc Orbi Med Capit...、Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of 4,572,148$. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth 92,340$.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: